Web Analytics
CleanSpark (CLSK) Is Down 5.5% After Special Dividend Shift And Texas Deal - Has The Bull Case Changed? | Deepscope News
MARKET

Select Market Data Region

 April 3, 2026 06:13 PM  finance.yahoo.com Positive

CleanSpark (CLSK) Is Down 5.5% After Special Dividend Shift And Texas Deal - Has The Bull Case Changed?

Image

In March 2026, CleanSpark confirmed an amendment to its Series A Preferred Stock that removed ongoing quarterly dividends and replaced them with a one-time US$17.14 per-share special dividend for holders of record on March 19, while also advancing its Texas expansion with the acquisition of a second 300-megawatt ERCOT-approved campus. At the same time, CleanSpark is tightly linked to Bitcoin’s recovery, faces an upcoming earnings report expected to show lower year-on-year figures, and continues to carry a very positive analyst consensus, all contributing to heightened attention on its business outlook. Next, we’ll examine how the Texas capacity expansion and earnings uncertainty influence CleanSpark’s existing investment narrative and risk profile.

Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.

CleanSpark Investment Narrative Recap

To own CleanSpark, you need to believe that the company can keep turning cheap, scaleable power into competitive Bitcoin production, despite its dependence on Bitcoin prices and regulatory conditions. The latest Texas expansion reinforces the capacity-driven upside story, while the amended Series A terms appear largely separate from the main near term catalyst, which is the upcoming earnings report expected to show weaker year on year figures. That report still looks like the key near term swing factor for sentiment.

The Texas acquisition of a second 300 megawatt ERCOT approved campus is the most relevant development here, because it speaks directly to CleanSpark’s core catalyst: expanding low cost, self operated infrastructure to grow Bitcoin output. Set against a share price that has fallen about 24% year to date and an earnings release that may highlight ongoing losses, this added capacity sharpens the contrast between long term scaling ambitions and the shorter term financial pressure.

Yet, in contrast, investors should be aware that CleanSpark’s tight link to Bitcoin prices and upcoming earnings report could...

Read the full narrative on CleanSpark (it's free!)

CleanSpark's narrative projects $1.5 billion revenue and $319.0 million earnings by 2028.

Uncover how CleanSpark's forecasts yield a $23.16 fair value, a 163% upside to its current price.

Exploring Other PerspectivesCLSK 1-Year Stock Price Chart

By contrast, the most bearish analysts highlight that even with revenue once modeled to grow about 23% annually to roughly US$1.5 billion, they still see prolonged unprofitability and stress that heavy capex and roughly US$820 million of debt could become far more painful if mining economics weaken, so it is worth weighing these downside scenarios alongside the Texas expansion story.

Story Continues

Explore 10 other fair value estimates on CleanSpark - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

A great starting point for your CleanSpark research is our analysis highlighting 3 important warning signs that could impact your investment decision. Our free CleanSpark research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CleanSpark's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

Find 62 companies with promising cash flow potential yet trading below their fair value. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CLSK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments

Read original source